Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

ARMP US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Armata Pharmaceuticals, Inc.(ARMP US)

Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

ARMP US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Armata Pharmaceuticals, Inc.(ARMP US)

Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Armata Pharmaceuticals, Inc. — Company Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.

Sector
Materials
Industry
Paper & Forest Products
Exchange
UA
CEO
Deborah L. Birx
Headquarters
Los Angeles, CA, US
IPO Date
May 20, 1994
Employees
61
Website
www.armatapharma.com

Key Metrics

Price
$3.52
Market Cap
$129.22M
Revenue (TTM)
$789.00K
Net Income (TTM)
$-115346000.00
EPS (TTM)
-3.16
P/E (TTM)
-0.46
P/B (TTM)
-0.41
Dividend Yield
0.00%
ROE (TTM)
37.02%
ROA (TTM)
-165.25%
Operating Margin
-11.13%
Beta
0.33

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.

Website
www.armatapharma.com
Location
Los Angeles, CA, US
Phone858 829 0829
Employees61
CEODeborah L. Birx
Sector
Materials
Industry
Paper & Forest Products
IPO DateMay 20, 1994

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(1.1K)

Expand
  • 10-QQ3ended 30 Sept 202612 Nov
  • 8-K​​​​​​​​​​ ​ ​September 30, 2026​ ​ ​December 31, 2025​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$18,317​$8,688​Prepaid expenses and other current assets​1,073​1,508​Other receivables​​3,209​​472​Total current assets​22,599​10,668​Property and equipment, net​10,799​12,194​Operating lease right-of-use asset​32,378​33,911​Intangible assets, net​​13,746​​13,746​Other long-term assets​4,956​6,363​Total assets​$84,478​$76,882​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$8,607​$8,947​Convertible Loan, current​​94,309​​—​Term debt, current​​83,862​​—​Total current liabilities​186,778​8,947​Convertible Loan, non-current​​—​​153,860​Term debt, non-current​​43,299​​103,061​Operating lease liabilities, net of current portion​​25,452​​26,533​Deferred tax liability​​3,077​​3,077​Total liabilities​258,606​295,478​Total stockholders’ deficit​(174,128)​(218,596)​Total liabilities and stockholders’ deficit​$84,478​$76,882​12 Nov
  • 8-KOther Events23 Sep
  • 8-KRegulation FD Disclosure14 Sep
  • 10-QQ2ended 30 Jun 202612 Aug
  • 8-K​​​​​​​​​​ ​ ​June 30, 2026​ ​ ​December 31, 2025​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$23,952​$8,688​Prepaid expenses and other current assets​673​1,508​Other receivables​​2,532​​472​Total current assets​27,157​10,668​Property and equipment, net​11,230​12,194​Operating lease right-of-use asset​32,884​33,911​Intangible assets, net​​13,746​​13,746​Other long-term assets​4,933​6,363​Total assets​$89,950​$76,882​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$8,715​$8,947​Convertible Loan, current​​163,904​​—​Term debt, current​​77,580​​—​Total current liabilities​250,199​8,947​Convertible Loan, non-current​​—​​153,860​Term debt, non-current​​42,024​​103,061​Operating lease liabilities, net of current portion​​25,823​​26,533​Deferred tax liability​​3,077​​3,077​Total liabilities​321,123​295,478​Total stockholders’ deficit​(231,173)​(218,596)​Total liabilities and stockholders’ deficit​$89,950​$76,882​12 Aug
  • 8-KRegulation FD Disclosure20 Jul
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers20 Jul
  • Form 4Birx Deborah14 Jul
  • 8-KRegulation FD Disclosure13 Jul
  • S-8Registration statement (employee benefit plan)10 Jul
  • 8-K/ADeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers24 Jun
  • 8-KOther Events23 Jun
  • 8-KSubmission of Matters to a Vote of Security Holders16 Jun
  • SC 13D/AArmata Pharmaceuticals, Inc.13 May
  • 10-QQ1ended 31 Mar 202613 May
  • 8-K​​​​​​​​​​ ​ ​March 31, 2026​ ​ ​December 31, 2025​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$4,754​$8,688​Prepaid expenses and other current assets​1,145​1,508​Other receivables​​47​​472​Total current assets​5,946​10,668​Property and equipment, net​11,780​12,194​Operating lease right-of-use asset​33,395​33,911​Intangible assets, net​​13,746​​13,746​Other long term assets​4,933​6,363​Total assets​$69,800​$76,882​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$9,228​$8,947​Total current liabilities​9,228​8,947​Convertible loan, non-current​​254,922​​153,860​Term debt, non-current​​87,976​​103,061​Operating lease liabilities, net of current portion​​26,183​​26,533​Deferred tax liability​​3,077​​3,077​Total liabilities​381,386​295,478​Total stockholders’ deficit​(311,586)​(218,596)​Total liabilities and stockholders’ deficit​$69,800​$76,882​13 May
  • 8-KRegulation FD Disclosure7 May
  • Form 4Gilmer Daniel B.28 Apr
  • Form 3Gilmer Daniel B.28 Apr

News

  • Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Beats Revenue Estimates12 Nov
  • Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update12 Nov
  • Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States7 Oct
  • Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program23 Sep
  • Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development23 Sep
  • Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates21 Sep
  • Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA0214 Sep
  • Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference10 Sep
  • Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials3 Sep

Mentions in Filings

  • ***Steve R. Martin*** has served as a member of our Board since August 2020. Mr. Martin was formerly Senior Vice President and Chief Financial Officer of <strong>Armata Pharmaceuticals, Inc.</strong>, a clinical development stage biotechnology company listed on the New York Stock Exchange, from January 2016 until his retirement from the position in June 2022. Previously, Mr. Martin served as Senior Vice President and Chief Financial Officer of Applied Proteomics, …
    Ensysce Biosciences, Inc.Armata Pharmaceuticals, Inc.·DEF 14A - Definitive proxy statement·Q4 26·12 Nov
  • … by the FDA on December 12, 2025, for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, we own other strategic healthcare assets, such as a significant equity stake in <strong>Armata Pharmaceuticals, Inc.</strong>, a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases. We also have economic interests in several other healthcare companies through our portfolio …
    Innoviva, Inc.Armata Pharmaceuticals, Inc.·10-Q - Quarterly report Q3·Q3 26·4 Nov
  • ***Steve R. Martin*** has served as a member of our Board since August 2020. Mr. Martin was formerly Senior Vice President and Chief Financial Officer of <strong>Armata Pharmaceuticals, Inc.</strong>, a clinical development stage biotechnology company listed on the New York Stock Exchange, from January 2016 until his retirement from the position in June 2022. Previously, Mr. Martin served as Senior Vice President and Chief Financial Officer of Applied Proteomics, …
    Ensysce Biosciences, Inc.Armata Pharmaceuticals, Inc.·PRE 14A - Preliminary proxy statement·Q4 26·30 Oct
  • … armaceutical (NASDAQ: OHRP) | | 7 | | 6/10/2019 | Oncternal Therapeutics, Inc. | GTx, Inc. (NASDAQ: GTXI) | | 9 | | 6/9/2019 | Edesa Biotech Inc. | Stellar Biotechnologies, Inc. (NASDAQ: SBOT) | | 2 | | 5/9/2019 | <strong>Armata Pharmaceuticals</strong> (f.k.a C3J) | Ampliphi Biosciences (NYSE: APHB) | | 10 | | 5/6/2019 | Adynxx, Inc. | Alliqua BioMedical, Inc. (NASDAQ: ALQA) | | 3 | | 4/23/2019 | Mereo BioPharma (AIM: MPH) | Oncomed Pharmaceuticals (NASDAQ: OMED …
    Sonic Holdco, Inc.Armata Pharmaceuticals, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·6 Nov
  • | --- | --- | | • | **Equity and long-term investments:** net unfavorable changes in fair value of equity and long-term investments totaled $139.5 million, primarily attributable to a decline in the stock price of <strong>Armata Pharmaceuticals</strong> at quarter-end.As of September 30, 2026**,** Innoviva’s strategic healthcare investments were valued at $535.5 million, consisting of $323.7 million invested in Armata Pharmaceuticals, $179.9 million in other stra …
    Innoviva, Inc.Armata Pharmaceuticals, Inc.·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·4 Nov
  • … armaceutical (NASDAQ: OHRP) | | 7 | | 6/10/2019 | Oncternal Therapeutics, Inc. | GTx, Inc. (NASDAQ: GTXI) | | 9 | | 6/9/2019 | Edesa Biotech Inc. | Stellar Biotechnologies, Inc. (NASDAQ: SBOT) | | 2 | | 5/9/2019 | <strong>Armata Pharmaceuticals</strong> (f.k.a C3J) | Ampliphi Biosciences (NYSE: APHB) | | 10 | | 5/6/2019 | Adynxx, Inc. | Alliqua BioMedical, Inc. (NASDAQ: ALQA) | | 3 | | 4/23/2019 | Mereo BioPharma (AIM: MPH) | Oncomed Pharmaceuticals (NASDAQ: OMED …
    Boundless Bio, Inc.Armata Pharmaceuticals, Inc.·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·3 Nov

Key Stats

Trading

Px/Chg 1D$3.52 / +6.34%
Prev Close$5.84
% of 52Wk H35.62%
Avg Volume83.94K
Beta0.33
Mkt Cap129.22M
FD Mkt Cap213.66M

Float

Shrs Out/Float36.71M / 11.43M
Short Float0.04%
Days to Cover1.46
Stock Repurchased$0.00

Current Valuation

EV498.14M
EV/EBITDA-1.90
EV/Sales168.41
P/B-0.41
P/S43.69
FCF Yield-4.52%
ROE37.02%
ROA-165.25%
Current Ratio0.64

Estimates

P/E-0.46
Est P/E0.00
Est EPS-0.38
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-1.81-1.25-1.31-2.71-2.63-1.14
Price / Sales40.988.4119.999.920.00166.57
Price / Book Value-0.911.28-2.82-1.07-1.50-0.42
Price / Free Cash Flow-15.08-1.33-1.63-1.30-48.63-22.48
ENTERPRISE VALUE METRICS
Enterprise Value310.680.3197.4168.6606.4500.3
Enterprise Value / Sales144.9814.5743.5932.580.00634.15
Enterprise Value / EBITDA-3.80-2.23-3.02-4.10-5.09-4.58
Enterprise Value / EBIT-3.75-2.17-2.97-3.97-5.08-4.56

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue2.3%4.55.54.55.24.9
Gross Income—-15.5-29.53.6-29.33.4
EBITDA63.2%-21.9-36.1-65.4-41.1-155.7
EBIT61.5%-23.1-36.9-66.4-42.4-157.2
Net Income65.5%-23.2-36.9-69.0-18.9-173.8
EPS (Diluted)49.5%-0.96-1.08-1.91-0.52-4.80
BALANCE SHEET
Cash & ST Inv-4.1%10.314.913.59.38.7
Total Assets2.5%69.8107.998.486.476.9
Total Liabilities60.6%44.471.8130.4134.5295.5
Total Shareholder Equity—25.436.1-32.1-48.0-218.6
CASH FLOW
Net Operating Cash Flow2.2%-23.6-32.5-47.4-37.6-25.8
Cap Ex-19.7%-1.3-2.2-8.1-1.9-0.5
Free Cash Flow1.4%-24.9-34.7-55.6-39.4-26.3

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)3.62
Basic Shares36.71
Market Cap132.9
Diluted Shares62.04
Fully Diluted Shares Outstanding62.04
Fully Diluted Market Cap224.6
+Consolidated Debt314.0
−In-the-Money Convertible Debt—
+Capital Leases25.8
+Operating Leases—
−Cash & Equivalents-24.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value422.9

Related companies

Amgen Inc

AMGN US

Gilead Sciences, Inc.

GILD US

Intuitive Surgical Inc

ISRG US

Moderna, Inc.

MRNA US

Argenx Se

ARGX US

Edwards Lifesciences Corporation

EW US

Revolution Medicines, Inc.

RVMD US

Biogen Inc.

BIIB US

BioNTech SE

BNTX US

STERIS plc

STE US

Nordson Corp

NDSN US

Tyson Foods, Inc.

TSN US

Armata Pharmaceuticals, Inc. — Company Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.

Sector
Materials
Industry
Paper & Forest Products
Exchange
UA
CEO
Deborah L. Birx
Headquarters
Los Angeles, CA, US
IPO Date
May 20, 1994
Employees
61
Website
www.armatapharma.com

Key Metrics

Price
$3.52
Market Cap
$129.22M
Revenue (TTM)
$789.00K
Net Income (TTM)
$-115346000.00
EPS (TTM)
-3.16
P/E (TTM)
-0.46
P/B (TTM)
-0.41
Dividend Yield
0.00%
ROE (TTM)
37.02%
ROA (TTM)
-165.25%
Operating Margin
-11.13%
Beta
0.33

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.

Website
www.armatapharma.com
Location
Los Angeles, CA, US
Phone858 829 0829
Employees61
CEODeborah L. Birx
Sector
Materials
Industry
Paper & Forest Products
IPO DateMay 20, 1994

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(1.1K)

Expand
  • 10-QQ3ended 30 Sept 202612 Nov
  • 8-K​​​​​​​​​​ ​ ​September 30, 2026​ ​ ​December 31, 2025​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$18,317​$8,688​Prepaid expenses and other current assets​1,073​1,508​Other receivables​​3,209​​472​Total current assets​22,599​10,668​Property and equipment, net​10,799​12,194​Operating lease right-of-use asset​32,378​33,911​Intangible assets, net​​13,746​​13,746​Other long-term assets​4,956​6,363​Total assets​$84,478​$76,882​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$8,607​$8,947​Convertible Loan, current​​94,309​​—​Term debt, current​​83,862​​—​Total current liabilities​186,778​8,947​Convertible Loan, non-current​​—​​153,860​Term debt, non-current​​43,299​​103,061​Operating lease liabilities, net of current portion​​25,452​​26,533​Deferred tax liability​​3,077​​3,077​Total liabilities​258,606​295,478​Total stockholders’ deficit​(174,128)​(218,596)​Total liabilities and stockholders’ deficit​$84,478​$76,882​12 Nov
  • 8-KOther Events23 Sep
  • 8-KRegulation FD Disclosure14 Sep
  • 10-QQ2ended 30 Jun 202612 Aug
  • 8-K​​​​​​​​​​ ​ ​June 30, 2026​ ​ ​December 31, 2025​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$23,952​$8,688​Prepaid expenses and other current assets​673​1,508​Other receivables​​2,532​​472​Total current assets​27,157​10,668​Property and equipment, net​11,230​12,194​Operating lease right-of-use asset​32,884​33,911​Intangible assets, net​​13,746​​13,746​Other long-term assets​4,933​6,363​Total assets​$89,950​$76,882​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$8,715​$8,947​Convertible Loan, current​​163,904​​—​Term debt, current​​77,580​​—​Total current liabilities​250,199​8,947​Convertible Loan, non-current​​—​​153,860​Term debt, non-current​​42,024​​103,061​Operating lease liabilities, net of current portion​​25,823​​26,533​Deferred tax liability​​3,077​​3,077​Total liabilities​321,123​295,478​Total stockholders’ deficit​(231,173)​(218,596)​Total liabilities and stockholders’ deficit​$89,950​$76,882​12 Aug
  • 8-KRegulation FD Disclosure20 Jul
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers20 Jul
  • Form 4Birx Deborah14 Jul
  • 8-KRegulation FD Disclosure13 Jul
  • S-8Registration statement (employee benefit plan)10 Jul
  • 8-K/ADeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers24 Jun
  • 8-KOther Events23 Jun
  • 8-KSubmission of Matters to a Vote of Security Holders16 Jun
  • SC 13D/AArmata Pharmaceuticals, Inc.13 May
  • 10-QQ1ended 31 Mar 202613 May
  • 8-K​​​​​​​​​​ ​ ​March 31, 2026​ ​ ​December 31, 2025​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$4,754​$8,688​Prepaid expenses and other current assets​1,145​1,508​Other receivables​​47​​472​Total current assets​5,946​10,668​Property and equipment, net​11,780​12,194​Operating lease right-of-use asset​33,395​33,911​Intangible assets, net​​13,746​​13,746​Other long term assets​4,933​6,363​Total assets​$69,800​$76,882​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$9,228​$8,947​Total current liabilities​9,228​8,947​Convertible loan, non-current​​254,922​​153,860​Term debt, non-current​​87,976​​103,061​Operating lease liabilities, net of current portion​​26,183​​26,533​Deferred tax liability​​3,077​​3,077​Total liabilities​381,386​295,478​Total stockholders’ deficit​(311,586)​(218,596)​Total liabilities and stockholders’ deficit​$69,800​$76,882​13 May
  • 8-KRegulation FD Disclosure7 May
  • Form 4Gilmer Daniel B.28 Apr
  • Form 3Gilmer Daniel B.28 Apr

News

  • Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Beats Revenue Estimates12 Nov
  • Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update12 Nov
  • Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States7 Oct
  • Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program23 Sep
  • Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development23 Sep
  • Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates21 Sep
  • Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA0214 Sep
  • Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference10 Sep
  • Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials3 Sep

Mentions in Filings

  • ***Steve R. Martin*** has served as a member of our Board since August 2020. Mr. Martin was formerly Senior Vice President and Chief Financial Officer of <strong>Armata Pharmaceuticals, Inc.</strong>, a clinical development stage biotechnology company listed on the New York Stock Exchange, from January 2016 until his retirement from the position in June 2022. Previously, Mr. Martin served as Senior Vice President and Chief Financial Officer of Applied Proteomics, …
    Ensysce Biosciences, Inc.Armata Pharmaceuticals, Inc.·DEF 14A - Definitive proxy statement·Q4 26·12 Nov
  • … by the FDA on December 12, 2025, for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, we own other strategic healthcare assets, such as a significant equity stake in <strong>Armata Pharmaceuticals, Inc.</strong>, a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases. We also have economic interests in several other healthcare companies through our portfolio …
    Innoviva, Inc.Armata Pharmaceuticals, Inc.·10-Q - Quarterly report Q3·Q3 26·4 Nov
  • ***Steve R. Martin*** has served as a member of our Board since August 2020. Mr. Martin was formerly Senior Vice President and Chief Financial Officer of <strong>Armata Pharmaceuticals, Inc.</strong>, a clinical development stage biotechnology company listed on the New York Stock Exchange, from January 2016 until his retirement from the position in June 2022. Previously, Mr. Martin served as Senior Vice President and Chief Financial Officer of Applied Proteomics, …
    Ensysce Biosciences, Inc.Armata Pharmaceuticals, Inc.·PRE 14A - Preliminary proxy statement·Q4 26·30 Oct
  • … armaceutical (NASDAQ: OHRP) | | 7 | | 6/10/2019 | Oncternal Therapeutics, Inc. | GTx, Inc. (NASDAQ: GTXI) | | 9 | | 6/9/2019 | Edesa Biotech Inc. | Stellar Biotechnologies, Inc. (NASDAQ: SBOT) | | 2 | | 5/9/2019 | <strong>Armata Pharmaceuticals</strong> (f.k.a C3J) | Ampliphi Biosciences (NYSE: APHB) | | 10 | | 5/6/2019 | Adynxx, Inc. | Alliqua BioMedical, Inc. (NASDAQ: ALQA) | | 3 | | 4/23/2019 | Mereo BioPharma (AIM: MPH) | Oncomed Pharmaceuticals (NASDAQ: OMED …
    Sonic Holdco, Inc.Armata Pharmaceuticals, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·6 Nov
  • | --- | --- | | • | **Equity and long-term investments:** net unfavorable changes in fair value of equity and long-term investments totaled $139.5 million, primarily attributable to a decline in the stock price of <strong>Armata Pharmaceuticals</strong> at quarter-end.As of September 30, 2026**,** Innoviva’s strategic healthcare investments were valued at $535.5 million, consisting of $323.7 million invested in Armata Pharmaceuticals, $179.9 million in other stra …
    Innoviva, Inc.Armata Pharmaceuticals, Inc.·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·4 Nov
  • … armaceutical (NASDAQ: OHRP) | | 7 | | 6/10/2019 | Oncternal Therapeutics, Inc. | GTx, Inc. (NASDAQ: GTXI) | | 9 | | 6/9/2019 | Edesa Biotech Inc. | Stellar Biotechnologies, Inc. (NASDAQ: SBOT) | | 2 | | 5/9/2019 | <strong>Armata Pharmaceuticals</strong> (f.k.a C3J) | Ampliphi Biosciences (NYSE: APHB) | | 10 | | 5/6/2019 | Adynxx, Inc. | Alliqua BioMedical, Inc. (NASDAQ: ALQA) | | 3 | | 4/23/2019 | Mereo BioPharma (AIM: MPH) | Oncomed Pharmaceuticals (NASDAQ: OMED …
    Boundless Bio, Inc.Armata Pharmaceuticals, Inc.·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·3 Nov

Key Stats

Trading

Px/Chg 1D$3.52 / +6.34%
Prev Close$5.84
% of 52Wk H35.62%
Avg Volume83.94K
Beta0.33
Mkt Cap129.22M
FD Mkt Cap213.66M

Float

Shrs Out/Float36.71M / 11.43M
Short Float0.04%
Days to Cover1.46
Stock Repurchased$0.00

Current Valuation

EV498.14M
EV/EBITDA-1.90
EV/Sales168.41
P/B-0.41
P/S43.69
FCF Yield-4.52%
ROE37.02%
ROA-165.25%
Current Ratio0.64

Estimates

P/E-0.46
Est P/E0.00
Est EPS-0.38
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-1.81-1.25-1.31-2.71-2.63-1.14
Price / Sales40.988.4119.999.920.00166.57
Price / Book Value-0.911.28-2.82-1.07-1.50-0.42
Price / Free Cash Flow-15.08-1.33-1.63-1.30-48.63-22.48
ENTERPRISE VALUE METRICS
Enterprise Value310.680.3197.4168.6606.4500.3
Enterprise Value / Sales144.9814.5743.5932.580.00634.15
Enterprise Value / EBITDA-3.80-2.23-3.02-4.10-5.09-4.58
Enterprise Value / EBIT-3.75-2.17-2.97-3.97-5.08-4.56

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue2.3%4.55.54.55.24.9
Gross Income—-15.5-29.53.6-29.33.4
EBITDA63.2%-21.9-36.1-65.4-41.1-155.7
EBIT61.5%-23.1-36.9-66.4-42.4-157.2
Net Income65.5%-23.2-36.9-69.0-18.9-173.8
EPS (Diluted)49.5%-0.96-1.08-1.91-0.52-4.80
BALANCE SHEET
Cash & ST Inv-4.1%10.314.913.59.38.7
Total Assets2.5%69.8107.998.486.476.9
Total Liabilities60.6%44.471.8130.4134.5295.5
Total Shareholder Equity—25.436.1-32.1-48.0-218.6
CASH FLOW
Net Operating Cash Flow2.2%-23.6-32.5-47.4-37.6-25.8
Cap Ex-19.7%-1.3-2.2-8.1-1.9-0.5
Free Cash Flow1.4%-24.9-34.7-55.6-39.4-26.3

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)3.62
Basic Shares36.71
Market Cap132.9
Diluted Shares62.04
Fully Diluted Shares Outstanding62.04
Fully Diluted Market Cap224.6
+Consolidated Debt314.0
−In-the-Money Convertible Debt—
+Capital Leases25.8
+Operating Leases—
−Cash & Equivalents-24.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value422.9

Related companies

Amgen Inc

AMGN US

Gilead Sciences, Inc.

GILD US

Intuitive Surgical Inc

ISRG US

Moderna, Inc.

MRNA US

Argenx Se

ARGX US

Edwards Lifesciences Corporation

EW US

Revolution Medicines, Inc.

RVMD US

Biogen Inc.

BIIB US

BioNTech SE

BNTX US

STERIS plc

STE US

Nordson Corp

NDSN US

Tyson Foods, Inc.

TSN US